Biotech Archives - Page 108 of 795

2 minute read

Why Is Liver Disease-Focused Pliant Therapeutics Stock Trading Lower Today?

February 5, 1:26 PM

Pliant Therapeutics reports 12-week interim data for bexotegrast in INTEGRIS-PSC Phase 2a trial. 320 mg group met primary and secondary endpoints, showing well-tolerance and reduction in liver fibrosis.

PLRX

2 minute read

What’s Going On With Eli Lilly Stock Today?

By Vandana Singh

February 5, 12:58 PM

Eli Lilly's stock surge, driven by the upcoming Q4 2023 results and the impact of FDA-approved weight-loss drug Zepbound.

CTLT

2 minute read

Why Is Eye Disease-Focused 4D Molecular Therapeutics Stock Shooting Higher Today?

By Vandana Singh

February 5, 12:17 PM

4D Molecular Therapeutics data in wet AMD treatment. Phase 2 PRISM trial shows promising results - 89% reduction in anti-VEGF injections, stable visual acuity.

FDMT

2 minute read

Singular Genomics Showcases New G4X Spatial Sequencer At AGBT And Announces Significant Advances In Throughput, Quality, And Usability For G4 Sequencing Platform

By Benzinga Newsdesk

February 5, 11:56 AM

Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, announced groundbreaking new products

OMIC

2 minute read

Weight Loss Drug’s New Entrant: Amgen To Compete With Novo Nordisk, Eli Lilly, As Investigational Weight Loss Drug Shows Encouraging Early Data

By Vandana Singh

February 5, 11:05 AM

Amgen's AMG 133 data. Promising results in obesity drug trials, including significant weight loss and improved metabolic markers.

AMGN

4 minute read

The American Cancer Society And Pfizer Announce A $15M, 3-Year Initiative To Bridge The Gap In Cancer Care Disparities

By Benzinga Newsdesk

February 5, 11:02 AM

The initiative, "Change the Odds: Uniting to Improve Cancer Outcomes" aims to enhance awareness of and access to cancer screening, clinical trials and support in medically underrepresented communities across the United

PFE

3 minute read

Yiviva Announces Memorandum Of Understanding With AstraZeneca To Develop Platforms, Technologies, And Innovative Therapeutics Through A Systems Biology Approach

By Benzinga Newsdesk

February 5, 10:04 AM

Yiviva, a clinical-stage, platform biotechnology company developing systems biology medicines to treat aging-related diseases, signed a memorandum of understanding (MOU) with AstraZeneca China to establish a research and

AZN

5 minute read

ARS Pharmaceuticals To Present Clinical Efficacy Data For neffy At 2024 AAAAI Annual Meeting

By Benzinga Newsdesk

February 5, 10:02 AM

Six posters and oral presentations to be presented, including efficacy data for neffy from two distinct clinical studies in oral food challenge induced anaphylaxis and chronic urticaria patients 100% response rate

SPRY

4 minute read

ImmunityBio Quality-Of-Life Study In BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function In The 71% Complete Responders Suggesting A Favorable Risk-Benefit Ratio For N-803 Plus BCG

By Benzinga Newsdesk

February 5, 10:01 AM

Patient Reported Outcomes (PROs) based on a May 16, 2022 data cutoff in the QUILT 3.032 trial indicate stability of physical function and global health in patients who completed PRO questionnaires and reached month 24

IBRX

2 minute read

Chikungunya Vaccine Maker Valneva Secures Non Dilutive Funding To Develop/Expand Its Clinical Pipeline

By Vandana Singh

February 5, 9:55 AM

Valneva sells FDA Priority Review Voucher for $103 million after FDA approval of Ixchiq, the world's first licensed chikungunya vaccine. Proceeds to boost R&D projects.

VALN